US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Cessatech updates the milestones for the coming year

· Great progress from the year 2024, including the commercialization agreement for CT001. · The US launch is still pending and our main focus for the coming period. · In 2025 we will work hard for new partnerships, new opportunities and get CT002 moving.On 23 December – Cessatech A/S (“Cessatech” or “the Company”) gives an update on the major milestones for the coming year. We are very pleased with the progress Cessatech has made during 2024, and this is truly the result of an incredible team-effort and partnership collaborations. During 2024 we closed the agreement with Proveca

Third Quarter Report Q3-2024

The Company has advanced well with its planned activities · Commercial partnership agreement with Proveca Ltd · Good progress with Paediatric Safety Study 0202 · Loan Facility Agreement extended to the year 2026 · US manufacturing and launch finalization in processCessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 July – 30 September 2024. The third quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports.  Third quarter financial results 2024 (1 July - 30

Cessatech announces that recruitment has today reached the halfway point for patient recruitment with 75 included patients in the Paediatric Study 0202

· 75 paediatric patients have now been recruited in Study 0202 · Study 0202 is the final required clinical study that will evaluate the safety and efficacy profile for CT001 in children · CT001 is a nasal spray for the treatment of acute pain in childrenOn 16 October – Cessatech A/S (“Cessatech” or “the Company”) announces that it has reached the halfway point for patient recruitment of its final study Paediatric Study 0202 in the development program of 0202. Study 0202 is the final required clinical study that will evaluate the safety and efficacy profile for CT001 in 150 children.

Cessatech and Proveca partnership - Q&A

Selected top 10 investor questionsOn 2 September – Cessatech A/S (“Cessatech” or “the Company”) releases a short Question and Answers (Q&A) overview, based on the positive feedback and questions received from investors following the agreement with Proveca on CT001. 1. How many potential partners have you had dialogue with for Europe?A: We have had several discussions with 6-7 companies, and the process has taken longer than expected. It was not until our meetings with Proveca that we felt confident about finding the best match for our objectives and aspirations. 2. What are your

Cessatech and Proveca announce world-wide excluding US commercial partnership for CT001

· Cessatech and Proveca enter an exclusive agreement for the commercialization of CT001 world-wide excluding US.   · Proveca has been granted a non-exclusive option to license Cessatech’s CT002 program. · Proveca is a global pharmaceutical company specialising in the development and licensing of medicines to address the unmet medical needs in children. Proveca is based in Manchester, England.On 26 August – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company has entered into an exclusive commercialization agreement with Proveca Ltd - a global pharmaceutical company

Second Quarter Report Q2-2024

The Company has advanced well with its planned activities · First patient dosed in Paediatric Safety Study 0202 · Superior simulated pain efficacy in children with CT001 · New member of the Board of Directors, Anders Dyhr D-Toft · US launch finalization and final approvals still ongoing...Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 April – 30 June 2024. The second quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports.  Second quarter financial results

Cessatech extends its undrawn Loan Facility Agreement to DKK 10 million to support the forthcoming US launch of its lead program CT001

· The Loan Facility Agreement with a group of investors from Investeringsselskabet MFO Private Equity A/S has been increased from DKK 5 million to DKK 10 million and the maturity extended until April 2026. · The new loan facility agreement provides Cessatech increased financial flexibility and support for the upcoming US launch of CT001. · To date Cessatech has not drawn on the facility and the Loan Facility Agreement can potentially be converted into shares on market conditions.On 12 August – Cessatech A/S (“Cessatech” or “the Company”) announces that the Company has extended the

Key Cessatech priorities for the rest of the year

· The US launch is almost there · More paediatric data to be presented at IASP 2024, World Congress on Pain · Commercial partnerships for Europe is also a key priorityOn 2 August 2024 Cessatech A/S ("Cessatech" or the "Company") has given an update for its key priorities for the remaing part of this year. The  short update includes the Company's key priorities and some of the most important events for the remaining part of 2024. The US launch is almost thereTiming of first sale - Both teams have been very busy preparing for the launch under the Early Access Program in the US -

Grant of incentive warrants to Employees, CEO and the Board of Directors

The Board of Directors of Cessatech A/S ("Cessatech" or the “Company”) has decided to grant a new incentive warrants to existing and new employees, to the CEO and the Board of Directors. The reason for the new warrant program is to retain and incentivize the employees, the Board of Directors and the CEO by offering a long-term ownership engagement, which will contribute to an alignment of interests between the warrant holders and the shareholders and promote long-term commitment to the Company’s development.Background and final termsOn 26 July 2024 it was decided to grant 250,000 warrants

Cessatech announces changes to the Board of Directors

Cessatech has today appointed Anders Dyhr Dombernowsky-Toft to the Board of Directors at the Company’s extraordinary general meeting. The appointment follows significant business progress over the last year. In addition, Peter Birk has resigned as a member of the Board of Directors to focus on other activities.Anders comes with long-standing medical and commercial background in senior leadership positions in both large pharma and small biotech. His experience with planning and execution of global launches makes him an important addition to our Board at this pivotal moment for Cessatech.

Minutes of the Extraordinary General Meeting – 5 July 2024

Cessatech A/S, CVR no. 41293055 (“Cessatech” or the “Company”) held its extraordinary general meeting on Friday 5 July 2024 at 08:30 (CET) at the Company's address Kanonbådsvej 2, 1437 København K.The agenda for the general meeting was as follows: 1. ELECTION OF THE CHAIRMAN OF THE MEETING 1. Attorney Anders Rubinstein was elected chairman of the meeting. The chairman of the meeting ascertained that none of the shareholders objected to the legality of the extraordinary general meeting and announced that the extraordinary general meeting had been duly convened and was legal and

Cessatech presents new data on paediatric pain relief at the PAGE conference in Rome favouring its lead candidate CT001

· Optimal drug exposure for effective pain management, significant findings revealed that relative drug exposure is much higher in young children. · Enhanced understanding of paediatric nasal drug delivery underscores the importance of age-specific considerations in nasal drug delivery. · Efficacy of CT001 administration. solidifies the opioid-sparing advantage of the CT001 formulation, making it a safer option for paediatric patients.On 28 June – Cessatech A/S (“Cessatech” or “the Company”) announces that the presentation is now available from the Population Approach Group Europe (

EXTRAORDINARY GENERAL MEETING

Cessatech A/S (“Cessatech” or the “Company”) hereby convenes the extraordinary general meeting to be held on Friday, 5 July 2024.The shareholders of Cessatech A/S The board of directors hereby convenes the extraordinary general meeting of Cessatech to be held physically on Friday 5 July 2024 at 8.30 (CET), at Kanonbådsvej 2, 1437 Copenhagen, Denmark. The agenda for the general meeting is as follows: 1. Election of the chairman of the meeting 2. Proposals from the board of directors 1. Proposal to elect Anders Dyhr Dombernowsky-Toft as a board member 2. Clarification of

Cessatech announces superior simulated pain efficacy in children favouring its lead candidate CT001 relative to its active comparators.

·The simulated pain reduction in NRS in children using CT001 was -87%, compared to -52%, -32% and +10% for sufentanil, ketamine and placebo respectively.  ·Estimates for the opioid sparing effect of ketamine showed a need for more than double the sufentanil exposure to get the same overall effect seen with the treatment of CT001.  ·The data supports the earlier reported data from the Dental Study 0205 showing the effectiveness of treatment with CT001. The full simulated data set will be presented at the PAGE conference in Rome 26-28 June.On 3 June – Cessatech A/S (“Cessatech”

Cessatech reports first patient dosed in final Safety Study 0202 of lead product candidate CT001

· First patient has been dosed in Safety Study 0202 of lead candidate CT001. · The Safety Study 0202 is an open-label, prospective study to assess safety, tolerability, analgesic effect, and feasibility of CT001 in 150 paediatric patients with moderate to severe pain, in the emergency setting. · Cessatech expects the study to be completed by the end of 2024.27 May - Cessatech A/S announces that the Safety Study 0202 has now been initiated with dosing of the first patient. The trial will assess safety, tolerability, analgesic effect, and feasibility of CT001 in 150 paediatric patients

First Quarter Report Q1-2024

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 January – 31 March 2024. The first quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports.First quarter financial results 2024 (1 January - 31 March):  · Net revenue was KDKK 0 · Operating result was KDKK -4.079  · Net result was KDKK -2.711 · Cash at bank end of the period was KDKK 15.041 · Earnings per share* was KDKK -0,16 · Solidity** was 95%  The Company has advanced well with its planned activities

Minutes from the Annual General Meeting in Cessatech A/S

Cessatech A/S, CVR no. 41293055 (“Cessatech” or the “Company”) held its Annual General Meeting on Wednesday 27 March 2023 at 09:00 (CET) at the Company's address Kanonbådsvej 2, 1437 København K.The agenda for the general meeting was as follows: 1. ELECTION OF CHAIRMAN OF THE MEETING 1. Mikkel Rostock-Jensen was elected chairman of the meeting. The chairman of the meeting ascertained that none of the shareholders objected to the legality of the annual general meeting and announced that the annual general meeting had been duly convened and was legal and competent in terms of all

Annual General Meeting - 27 March 2024

Cessatech A/S (“Cessatech” or the “Company”) hereby convenes the annual general meeting to be held on 27 March 2024.The shareholders of Cessatech A/S The board of directors hereby convenes the annual general meeting of Cessatech to be held on Thursday 27 March 2024 at 9.00 (CET) at the Company's address Kanonbådsvej 2, 1437 København K. The agenda for the general meeting is as follows: 1. ELECTION OF CHAIRMAN OF THE MEETING 2. REPORT ON THE ACTIVITIES OF THE COMPANY IN THE PAST FINANCIAL YEAR 3. PRESENTATION OF THE ANNUAL REPORT WITH AUDITORS’ REPORT FOR ADOPTION 4.

Cessatech A/S publishes Annual Report for the fiscal year 2023

Cessatech A/S (“Cessatech” or the “Company”) hereby publishes its annual report for the fiscal year 2023, which also includes the fourth quarter of 2023 financial reporting. The annual report is attached as a pdf. The report is also available on Cessatech’s website www.cessatech.com under ‘Fillings & Reports’.Full year 2023 for the period 1 January - 31 December (Q4’2023 results in brackets):  ·Net revenue was KDKK 0 (0)  ·Operating result was KDKK -22.510 (-4.852)  ·Net result was KDKK -26.527 (-12.009)  ·Cash at bank end of the period was KDKK 3.373 (3.373)

CESSATECH ANNOUNCES RESULT OF WARRANT EXERCISE FOR WARRANTS OF SERIES TO2

Copenhagen, Denmark, January 30, 2024 - Today, Cessatech A/S ("Cessatech” or the "Company") announces the outcome of the exercise of warrants of series TO2 (the "Warrants"), which were issued in connection with the Company's rights issue of units announced on October 19, 2022. In total 3,636,339 Warrants were exercised, corresponding to approximately 94.7 percent of the total number of outstanding Warrants, for subscription of 3,636,339 shares at an exercise price of DKK 4.71 per share. Cessatech will receive approximately DKK 17.1 million before issuing costs.BackgroundCessatech

Correction: LAST DAY OF TRADING IN WARRANTS OF SERIES TO2 IN CESSATECH IS TOMORROW, JANUARY 24, 2024

In the press release published earlier today the MAR label was placed by mistake. Copenhagen, Denmark, January 23, 2024 - Tomorrow, January 24, 2024, is the last day of trading in warrants of series TO2 (the "Warrants"). The exercise period for the Warrants runs up to and including January 26, 2024. One (1) Warrant gives the right to subscribe for one (1) new share in Cessatech. The exercise price is DKK 4.71 per share. Note that Warrants not sold by tomorrow, January 24, 2024, or alternatively used to subscribe for shares no later than on January 26, 2024, expire without compensation to

LAST DAY OF TRADING IN WARRANTS OF SERIES TO2 IN CESSATECH IS TOMORROW, JANUARY 24, 2024

Copenhagen, Denmark, January 23, 2024 - Tomorrow, January 24, 2024, is the last day of trading in warrants of series TO2 (the "Warrants"). The exercise period for the Warrants runs up to and including January 26, 2024. One (1) Warrant gives the right to subscribe for one (1) new share in Cessatech. The exercise price is DKK 4.71 per share. Note that Warrants not sold by tomorrow, January 24, 2024, or alternatively used to subscribe for shares no later than on January 26, 2024, expire without compensation to the holder.NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART,

CESSATECH ANNOUNCES THAT MANAGEMENT AND BOARD HAVE EXERCISED ALL THEIR WARRANTS OF SERIES TO2

Copenhagen, Denmark, January 22, 2024 – Cessatech A/S ("Cessatech" or the "Company") announces that all members of the Company’s Senior Management and Board of Directors, including CEO Jes Trygved and Chairman of the Board of Directors, Martin Olin, have exercised all their warrants of Series TO2. In totality, Cessatech’s Senior Management and Board of Directors will subscribe for approximately DKK 1.75 million through the exercise of their TO2 warrants.If all the warrants of series TO2 are exercised, the Company will receive approximately DKK 18.1 million before issuing costs. For the

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe